Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xoma gains on Novartis IL-1 beta mAb deals

Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN) worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab (XOMA 052). The company also granted Novartis a non-exclusive license to IP covering IL-1 beta-targeting antibodies to

Read the full 426 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers